Literature DB >> 33051740

Verification of the Optimal Interval Before Esophagectomy After Preoperative Neoadjuvant Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer.

Akiyuki Wakita1, Satoru Motoyama2, Yusuke Sato2, Yushi Nagaki2, Hiromu Fujita2, Kaori Terata2, Kazuhiro Imai2, Yoshihiro Minamiya2.   

Abstract

BACKGROUND: The interval between preoperative chemoradiotherapy and surgery reportedly affects perioperative outcomes and survival; however, the optimal interval in esophageal cancer patients remains uncertain.
OBJECTIVE: Our aim was to determine whether a prolonged interval between preoperative neoadjuvant chemoradiotherapy (NACRT) and esophagectomy affects the outcomes of esophageal cancer patients.
METHODS: A total of 131 patients with esophageal cancer received curative surgery following NACRT at Akita University Hospital between 2009 and 2017. We divided these patients into two groups based on the median interval from NACRT to esophagectomy, and compared the rates of pathological complete response (pCR), surgical outcomes, and survival.
RESULTS: The median interval from NACRT to esophagectomy was 39 days (range 21-95). Of the 131 patients, 70 (53%) received esophagectomy after 39 days or more from completion of NACRT. There were no significant differences in the clinicopathological features, including pCR rates, between the two groups. Prolongation of the interval from NACRT to esophagectomy was significantly associated with an increased rate of anastomotic leakage and recurrent laryngeal nerve palsy (p = 0.0225 and p = 0.0022, respectively); however, no association with overall survival was detected.
CONCLUSIONS: A prolonged interval between NACRT and esophagectomy had no impact on pCR rates or survival. However, delaying esophagectomy may increase the likelihood of surgical complications such as anastomotic leakage and recurrent laryngeal nerve palsy.

Entities:  

Mesh:

Year:  2020        PMID: 33051740     DOI: 10.1245/s10434-020-09206-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  1 in total

1.  Chemoradiotherapy for treatment of esophageal cancer in Japan: current status and perspectives.

Authors:  Kohei Shitara; Kei Muro
Journal:  Gastrointest Cancer Res       Date:  2009-03
  1 in total
  1 in total

Review 1.  The Key Clinical Questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer-A Review.

Authors:  Dan Han; Baosheng Li; Qian Zhao; Hongfu Sun; Jinling Dong; Shaoyu Hao; Wei Huang
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.